ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · Real-Time Price · USD
0.430
+0.013 (2.99%)
Nov 4, 2024, 4:00 PM EST - Market closed
ImmunoPrecise Antibodies Income Statement
Financials in millions CAD. Fiscal year is May - April.
Millions CAD. Fiscal year is May - Apr.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jul '24 Jul 31, 2024 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 | Apr '20 Apr 30, 2020 | 2019 - 2015 |
| Revenue | 24.09 | 24.52 | 20.67 | 19.36 | 17.91 | 14.06 | Upgrade
|
| Revenue Growth (YoY) | 11.21% | 18.65% | 6.72% | 8.11% | 27.41% | 28.66% | Upgrade
|
| Cost of Revenue | 12.48 | 12.47 | 9.1 | 8.38 | 6.51 | 6.1 | Upgrade
|
| Gross Profit | 11.61 | 12.05 | 11.56 | 10.98 | 11.4 | 7.95 | Upgrade
|
| Selling, General & Admin | 18.77 | 19.14 | 18.19 | 18.06 | 10.59 | 8.24 | Upgrade
|
| Research & Development | 4.74 | 4.04 | 14.1 | 7.66 | 1.97 | 0.45 | Upgrade
|
| Operating Expenses | 26.24 | 26.15 | 36.71 | 27.73 | 18.06 | 12.05 | Upgrade
|
| Operating Income | -14.62 | -14.09 | -25.14 | -16.75 | -6.65 | -4.09 | Upgrade
|
| Interest Expense | -0.21 | -0.02 | -0.03 | -0.09 | -0.64 | -0.7 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.02 | 0.12 | 0.28 | 0.28 | 0.05 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.01 | 0.09 | 0.23 | 0.63 | -1.23 | 0.08 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.2 | 0.33 | 0.33 | 0.08 | -0.22 | -0.73 | Upgrade
|
| EBT Excluding Unusual Items | -14.62 | -13.67 | -24.49 | -15.85 | -8.47 | -5.4 | Upgrade
|
| Merger & Restructuring Charges | - | - | -0.8 | - | - | - | Upgrade
|
| Impairment of Goodwill | -11.16 | -11.16 | -2.46 | - | - | - | Upgrade
|
| Asset Writedown | -3.87 | -3.87 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 2.47 | 0.11 | Upgrade
|
| Pretax Income | -29.65 | -28.7 | -27.75 | -15.85 | -6 | -5.29 | Upgrade
|
| Income Tax Expense | -1.89 | -1.53 | -1.19 | 0.86 | 1.35 | -0.35 | Upgrade
|
| Net Income | -27.76 | -27.18 | -26.56 | -16.71 | -7.34 | -4.95 | Upgrade
|
| Net Income to Common | -27.76 | -27.18 | -26.56 | -16.71 | -7.34 | -4.95 | Upgrade
|
| Shares Outstanding (Basic) | 26 | 26 | 25 | 20 | 16 | 14 | Upgrade
|
| Shares Outstanding (Diluted) | 26 | 26 | 25 | 20 | 16 | 14 | Upgrade
|
| Shares Change (YoY) | 4.73% | 2.97% | 26.46% | 19.51% | 20.88% | 8.67% | Upgrade
|
| EPS (Basic) | -1.06 | -1.06 | -1.07 | -0.85 | -0.45 | -0.36 | Upgrade
|
| EPS (Diluted) | -1.06 | -1.06 | -1.07 | -0.85 | -0.45 | -0.36 | Upgrade
|
| Free Cash Flow | -7.04 | -5.64 | -21.33 | -10.99 | -2.03 | -1.85 | Upgrade
|
| Free Cash Flow Per Share | -0.27 | -0.22 | -0.86 | -0.56 | -0.12 | -0.14 | Upgrade
|
| Gross Margin | 48.20% | 49.16% | 55.95% | 56.72% | 63.67% | 56.58% | Upgrade
|
| Operating Margin | -60.69% | -57.48% | -121.67% | -86.49% | -37.14% | -29.12% | Upgrade
|
| Profit Margin | -115.22% | -110.85% | -128.53% | -86.29% | -40.98% | -35.19% | Upgrade
|
| Free Cash Flow Margin | -29.22% | -23.02% | -103.21% | -56.74% | -11.32% | -13.18% | Upgrade
|
| EBITDA | -11.51 | -10.37 | -21.31 | -12.98 | -4.6 | -2.39 | Upgrade
|
| EBITDA Margin | -47.75% | -42.30% | -103.11% | -67.03% | -25.66% | -16.99% | Upgrade
|
| D&A For EBITDA | 3.12 | 3.72 | 3.84 | 3.77 | 2.06 | 1.71 | Upgrade
|
| EBIT | -14.62 | -14.09 | -25.14 | -16.75 | -6.65 | -4.09 | Upgrade
|
| EBIT Margin | -60.69% | -57.48% | -121.67% | -86.49% | -37.14% | -29.12% | Upgrade
|
| Advertising Expenses | - | - | - | - | 0.69 | 0.38 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.